Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 334Active not recruiting 62Terminated 51Unknown 50Recruiting 39Withdrawn 28Not yet recruiting 10Suspended 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Triple Negative Breast Neoplasms 2Breast Neoplasms 2Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Mesothelioma 1Melanoma 1Lung Neoplasms 1Esophageal Neoplasms 1

Interventions

Trastuzumab 2Taxes 2Paclitaxel 2Fluorouracil 2Cyclophosphamide 2trastuzumab biosimilar HLX02 1tivozanib 1taletrectinib 1palbociclib 1eribulin 1atezolizumab 1Tomography, Optical Coherence 1Testosterone Propionate 1Testosterone 1Tamoxifen 1Tablets 1Specimen Handling 1Receptors, Chimeric Antigen 1Radiotherapy 1PF-05280014 1Ontruzant 1Ogivri 1Neoadjuvant Therapy 1Methotrexate 1Mastectomy, Segmental 1Lisaftoclax 1Interpersonal Psychotherapy 1Interleukin-2 1Injections 1G(M1) Ganglioside 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Suspended × Breast Neoplasms × Paclitaxel × Clear all
NCT05751668 2026-04-07

Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel (Phase II)

Alliance for Clinical Trials in Oncology

Phase 2 Suspended
98 enrolled
Breast

Breast Neoplasms

NCT02037529 2024-08-20

Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer

Academic and Community Cancer Research United

Phase 3 Suspended
201 enrolled 19 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡